Countdown to GSMA Mobile World Congress Shanghai 2018 is On
With two weeks until Mobile World Congress Shanghai opens, the GSMA provided a final update on the event, including additional speakers confirmed for the keynote programme and 4 Years From Now (4YFN) Summit, as well as further details on exhibition features and partner programmes. Mobile World Congress Shanghai will be held 27-29 June at the Shanghai New International Expo Centre (SNIEC).
“We are counting down the days to Mobile World Congress Shanghai – we have an amazing programme lined up across the exhibition, the conference and the many other events and programmes taking place during the week,” said Michael O’Hara, Chief Marketing Officer. “Attendees will have the opportunity to discover a better future enabled by mobile, experiencing how mobile will positively impact consumers, industries, society and the economy.”
Additional Keynote Speakers Confirmed
The GSMA announced a number of additional keynote speakers for Mobile World Congress Shanghai, including executives representing the mobile operator community and other organisations across the broad ecosystem. New keynote speakers include:
- Edward Tian, Executive Chairman, AsiaInfo Technologies
- John Tsang, Chairman, Benefit Vantage and Former Financial Secretary, Hong Kong
- Shang Bing, Chairman, China Mobile
- Susana Tsui, CEO, Dentsu Aegis Network China
- Gloria Eisman Maraver, CEO, LightBee
Held over three days in Hall N5 of the SNIEC, the Mobile World Congress Shanghai conference programme will explore the key topics shaping the mobile industry, including 5G, artificial intelligence, the latest developments in devices, the future of vehicles and the Internet of Things (IoT), among many others. For further information on the conference, including agenda and speakers, visit www.mwcshanghai.com/conference-programmes/.
4YFN Summit: New Speakers and Sponsors
Focusing on startups, investors and corporations, the 4YFN programme offers unique connecting initiatives, including inspirational talks, technical workshops, networking activities, community outreach and the 4YFN Summit. The GSMA has confirmed that several new speakers from leading innovators will speak in the 4YFN Summit, which will be held 27-29 June, including:
- Catherine Yang, Head of AI, Baidu
- Celina Chew, President, Bayer Greater China
- Jiaqing Lu, Managing Director, Cash Capital
- Yang Wang, President, Cybernaut Investment Group
- Valentina Wu, Senior Director, Fosun Foundation
- Yingjie Wen, Managing Director, Level Constellation
- Jianghong Yu, Founding Partner, Mytech China
In addition, RobotUnion and Impact Growth have signed on as Supporting Partners of the Summit. For more information on the 4YFN Summit and the full 4YFN programme, visit: www.mwcshanghai.com/experiences/4yfn/.
GSMA Innovation City: Showcasing the Latest in Mobile
Activity in the GSMA Innovation City will reinforce the Mobile World Congress Shanghai event theme “Discover a Better Future”, highlighting how intelligent connectivity – leveraging 5G, the IoT, artificial intelligence (AI) and big data – can deliver a smarter and more sustainable future. The Innovation City will showcase these technologies and much more through a range of hands-on experiential demonstrations that illustrate how mobile impacts virtually every aspect of life, in sectors such as transport, health, agriculture, industry, home and retail.
Leading brands including BICS, Continental, Huawei, Internet Finance Authentication Alliance (IFAA), Migu, myFC, PwC, Ratta, SI-TECH and Zhejiang Panshi Information Technology will participate in the City, alongside key GSMA programmes including Future Networks, Identity, Industry Purpose and the Internet of Things. For more information, visit www.mwcshanghai.com/exhibition/gsma-innovation-city/.
Tencent Cloud, vivo Confirmed in Exhibition
Tencent Cloud and vivo become the latest companies to confirm their participation in the Mobile World Congress Shanghai showfloor, joining previously announced exhibitors and sponsors including China Mobile, China Telecom, China Unicom, Ericsson, HTC, Huawei, Intel, Lenovo, Nokia, Qualcomm, Samsung LSI, Tata Communications, Vodafone, Volkswagen and ZTE, among many others. For more information on the exhibition, visit www.mwcshanghai.com/exhibition/.
Connected China Spotlights Mobile IoT Technologies
Located in the NEXTech Hall, Connected China will put the spotlight on 12 innovative developers, start-ups and companies focusing on Mobile IoT products and solutions. Spanning six key vertical applications for Mobile IoT including fire safety, industrial IoT, logistics, smart agriculture, smart city and smart home, the demonstrations range from intelligent freight management and smart air purifiers to pet trackers and wearable devices. For more information about Connected China, visit: www.mwcshanghai.com/iot/ .
New Partner Programmes and Workshops Added to Agenda
At Mobile World Congress Shanghai, partner programmes and workshops offer attendees another opportunity to engage with and gain perspectives from the top organisations in the industry. The GSMA announced nine new partner programmes taking place in Shanghai including:
Tuesday, 26 June
- China Mobile E·I Night
Wednesday, 27 June
- 2018 IOV Summit · Opening Ceremony of CMIM Network @MWC Shanghai
- Mobile Authentication Open Cooperation Summit 2018 (by China Mobile)
Thursday, 28 June
- 5G Automotive Association – Connected Mobility in Motion
- China Unicom 5G Ecological Strategy Conference
- China Unicom Network Transformation and 5G Strategy Launch
- China Unicom Network Transformation Conference
- China Unicom’s Smart City Forum: Smart Cities for Better Governance and Happier Lives
- Enterprise Ireland: Accelerate Your Growth with Irish Technology
For more information on the partner programmes at Mobile World Congress Shanghai, visit: www.mwcshanghai.com/conference-programmes/partner-programmes/.
Media Partners at Mobile World Congress Shanghai
CNN International is a Global Media Partner at Mobile World Congress Shanghai, as well as other global GSMA events. Additional media partners at Mobile World Congress Shanghai include Mobile World Live (Global Media Partner); BBC World News & BBC.com, Bloomberg Businessweek, CCTV2 and LinkedIn (Official Media Partners); and C114, People’s Posts and Telecommunications News and Tencent News (Strategic Media Partners). For a full list of media partners at Mobile World Congress Shanghai, visit www.mwcshanghai.com/about/sponsors-partners/ .
Get Involved at Mobile World Congress Shanghai 2018
For more information on Mobile World Congress Shanghai, including how to attend, exhibit, partner or sponsor, visit www.mwcshanghai.com. Follow developments and updates on Mobile World Congress Shanghai through our social media channels – follow us on Twitter at @GSMA and use #MWCS18, get regular updates through our LinkedIn Showcase Page at www.linkedin.com/company/mobile-world-congress-shanghai, and follow us on Facebook at www.facebook.com/mwcshanghai. In China, you can follow us on Sina Weibo weibo.com/mwcshanghai or search “GSMA_MWCS” in WeChat.
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 10:06 | Tiedote
Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an
STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 10:00 | Tiedote
Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe
Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 05:53 | Tiedote
Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and
CES Asia: Innovation at the Speed of 5G15.6.2018 17:59 | Tiedote
CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re
bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 13:00 | Tiedote
bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch
bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 13:00 | Tiedote
bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme